Roivant Sciences (Roivant Sciences) YoY EBITDA Growth : 1,271.18% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Roivant Sciences's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 1,271.18%.

Roivant Sciences's EBITDA per Share for the three months ended in Dec. 2023 was $6.06.

Roivant Sciences YoY EBITDA Growth Historical Data

The historical data trend for Roivant Sciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences YoY EBITDA Growth Chart

Roivant Sciences Annual Data

Trend

Mar21

Mar22

Mar23

YoY EBITDA Growth

-3.98

-21.54

Roivant Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial										-16.97	46.63	17.17	5.36	1,271.18

Roivant Sciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Roivant Sciences's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

	YoY EBITDA Growth (A: Mar. 2023 )
=	(EBITDA per Share (A: Mar. 2023 )	-	EBITDA per Share (A: Mar. 2022 ))	/	\| EBITDA per Share (A: Mar. 2022 ) \|
=	(-1.653	-	-1.36)	/	\| -1.36 \|
=	-21.54 %

Roivant Sciences's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(6.055	-	-0.517)	/	\| -0.517 \|
=	1,271.18 %

Roivant Sciences YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Roivant Sciences (Roivant Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

87S:Germany

Address

50 Broadway, 7th Floor, London, GBR, SW1H 0BD

Website

https://www.roivant.com

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Executives

Eric Venker	officer: President & COO	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester	director	C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold	director	6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp	10 percent owner, other: Director by Deputization	888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar	officer: Chief Accounting Officer	C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd.	10 percent owner	7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p.	10 percent owner	AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik	officer: CFO	SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy	director	C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 3060000